Anika Therapeutics (ANIK)
(Delayed Data from NSDQ)
$25.97 USD
+0.40 (1.56%)
Updated Apr 29, 2024 03:59 PM ET
After-Market: $25.97 0.00 (0.00%) 7:36 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANIK 25.97 +0.40(1.56%)
Will ANIK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ANIK based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIK
Is DexCom (DXCM) Outperforming Other Medical Stocks This Year?
Has DexCom (DXCM) Outpaced Other Medical Stocks This Year?
ANIK: What are Zacks experts saying now?
Zacks Private Portfolio Services
Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Other News for ANIK
Medicare Administrators looking to 'drastically shake up' wound care, says BTIG
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Anika Therapeutics: Strong Q4 Performance and Upbeat FY2024 Outlook Justify Buy Rating and Raised Price Target
Anika Therapeutics price target raised by $8 at Barrington, here's why